We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Reacting to concerns about good clinical practice at sites run by one of its trial contractors — Boston-based Care Access — Pfizer announced it will drop Care Access sites from its phase 3 Lyme disease vaccine trial, losing about 3,500 participants. Read More
Members of the Senate Commerce Committee heard testimony yesterday from panelists mostly in favor of a recently reintroduced bill that would compel pharmacy benefit managers (PBM) to be transparent about their pricing practices and to get them to stop unfair or deceptive conduct that drives up costs for consumers. Read More
Multiple drugmakers have filed amicus briefs to the U.S. Supreme Court refuting a broad patent claim by Amgen that — if upheld — could have sweeping implications in drug development. Read More
Madrigal Pharmaceuticals’ nonalcoholic steatohepatitis (NASH) drug resmetirom might be a cost-effective treatment for the disease if priced at no more than $12,820 per year, according to a draft cost-benefit analysis by the Institutes for Clinical and Economic Review (ICER). Read More
Will the Pharmaceutical Research and Manufacturers of America (PhRMA) start losing more members this year in the wake of the powerful lobbying group’s inability to stop the 2022 Inflation Reduction Act (IRA) and all its cost-cutting measures aimed at the pharmaceutical industry? Read More
The updated labeling says healthcare providers should tell patients that taking antithrombotic or thrombolytic medications with Aduhelm may increase the risk of bleeding in the brain. Read More
More than one-fifth of the new drugs approved by the FDA from 2017 through 2020 were either refused marketing authorization or not recommended for reimbursement in Australia, Canada, or the UK due to unfavorable benefit-to-risk profiles, uncertain clinical benefit or unacceptably high price. Read More